Astrazeneca Q2 Profits Up 22 Percent
From Associated Press (July 29, 2010)
LONDON -- AstraZeneca PLC has reported a 22 percent rise in second
quarter net profit and has also revealed that a key new drug -- its
blood thinner Brilinta -- has been given a thumbs up by an advisory
committee of the U.S. Food and Drug Administration.
The Anglo-Swedish drugmaker on Thursday posted net profit of $2.1 billion for the three months to June 30, compared with $1.72 billion in the same period a year ago.
Revenue rose 2.8 percent to $8.18 billion, from $7.96 billion.
FDA advisory committee members have voted 7 to 1 to recommend
the approval of Brilinta in patients with acute coronary syndrome,
or blocked arteries. The FDA usually follows the advice of its
advisory committee.
Posted: July 2010
